RTW Biotech's Avere to go public in US in reverse merger with NextCure
(Alliance News) - RTW Biotech Opportunities Ltd on Wednesday noted that portfolio holding Avere Therapeutics will go public via a reverse merger with Nasdaq-listed NextCure Inc. Read More